In the BioHarmony Drug Report Database

"Preview" Icon

Patisiran

Onpattro (patisiran) is an oligonucleotide pharmaceutical. Patisiran was first approved as Onpattro on 2018-08-10. It has been approved in Europe to treat familial amyloidosis. Onpattro’s patents are valid until 2035-08-27 (FDA).

 

Trade Name

 

Onpattro
 

Common Name

 

patisiran
 

ChEMBL ID

 

CHEMBL3989987
 

Indication

 

familial amyloidosis
 

Drug Class

 

Image (chem structure or protein)

Patisiran structure rendering